Sanatorio Allende | Departamento de Investigación Clínica

Research site

(Unclaimed)

Location

Av. Hipólito Yrigoyen 384, Cordoba, Cordoba, Argentina

Site insights

Top conditions

Top treatments

Atezolizumab

Carboplatin

Paclitaxel

Milvexian

Cytarabine

Pembrolizumab

Venetoclax

Tiragolumab

Fulvestrant

RO7434656

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 32 total trials

Locations recently updated

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Enrolling

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Drug: Fulvestrant

Drug: Dexamethasone Mouth Rinse

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PALOMA-3)

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantama...

Active, not recruiting

Advanced or Metastatic Non-small Cell Lung Cancer

Drug: Lazertinib

Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling

Acute Coronary Syndrome

Drug: Milvexian

Other: Placebo

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling

Ischemic Stroke; Ischemic Attack, Transient

Drug: Placebo

Drug: Milvexian

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of...

Active, not recruiting

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Drug: Cytarabine

Drug: Dexamethasone

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administere...

Enrolling

Non-small Cell Lung Cancer (NSCLC)

Drug: Atezolizumab

Drug: Placebo

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS)...

Active, not recruiting

Acute Myeloid Leukemia (AML)

Drug: Placebo

Drug: Venetoclax

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, b...

Enrolling

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)

Drug: Giredestrant

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with International Society of N...

Active, not recruiting

Lupus Nephritis

Drug: Placebo

Drug: MMF

A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RO7434656, a novel Antisense Oligonucleotide (ASO) therapy in...

Enrolling

Primary IgA Nephropathy

Drug: RO7434656

Drug: Placebo

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of GDC-1971 when administered in combination with atezolizum...

Enrolling

Advanced Solid Tumors

Metastatic Solid Tumors

Drug: Omeprazole

Drug: GDC-1971

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Pembrolizumab

Drug: M7824

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative t...

Enrolling

Non-small Cell Lung Cancer

Drug: Domvanalimab

Drug: Nab-paclitaxel